-
Seattle Genetics and Merck Partner
contractpharma
September 15, 2020
Seattle Genetics Inc. and Merck, known as MSD outside the United States and Canada, have announced two new strategic oncology collaborations.
-
Research backs use of liquid biopsy for personalised cancer care
pharmatimes
September 14, 2020
UK research has shown that a blood test is able to identify various mutations in advanced breast cancer and can thus match women to targeted treatment, adding further weight to evidence backing use of liquid biopsies for more personalised cancer care.
-
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance
contractpharma
September 07, 2020
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.
-
Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo
contractpharma
September 03, 2020
DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.
-
Bayer invests in cancer therapies developer Triumvira Immunologics
pharmaceutical-technology
August 31, 2020
Bayer’s investment unit Leaps by Bayer and Northpond Ventures led the $55m Series A funding round of cancer therapies developer Triumvira Immunologics.
-
Researchers develop technology to see inside cells
expresspharma
August 21, 2020
The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more.
-
Gilead and Tango Therapeutics partner for targeted cancer therapies
pharmaceutical-technology
August 19, 2020
Gilead Sciences has collaborated with Tango Therapeutics to discover, develop and commercialise targeted immune evasion therapies for cancer patients.
-
NHS adapts to pandemic with ‘COVID-friendly’ cancer treatments
pharmatimes
August 05, 2020
NHS chief executive Sir Simon Stevens has announced plans for a £160m initiative to roll-out ‘COVID-friendly’ cancer treatments for patients across the UK.
-
Immodulon, Champalimaud Foundation team up on ‘difficult to treat’ cancers
pharmatimes
August 04, 2020
London, UK-based Immodulon has teamed up with Lisbon, Portugal-based non-profit organisation the Champalimaud Foundation to research and examine the potential use of the experimental treatment IMM-101 in combination with other therapies ...
-
NHS People Plan to address new pandemic challenges
pharmatimes
July 31, 2020
NHS England has launched a new drive to put staff wellbeing at the heart of NHS recovery, with measures designed to address new pandemic challenges and improve physical and mental health support for staff.